BCR and diffuse large B-cell lymphoma: Lenalidomide is an immunomodulatory agent that downregulates IRF4/MUM1 and subsequently decreases BCR-dependent NF-κB activity in ABC-DLBCL cells in vitro and in tumor xenograft models66.